Jazz Pharmaceuticals (JAZZ) Stock Price, News, Quotes-Moomoo

English
中文繁體
中文简体

Download

Mobile

moomoo Desktop

The next-gen workspace

Download now

Click to view more download content

English
中文繁體
中文简体

Dark
Light

Open Account

Download

US Stock MarketDetailed Quotes

JAZZ Jazz Pharmaceuticals

Watchlist

134.950
+0.990+0.74%

Trading Feb 18 13:12 ET

8.16BMarket Cap19.11P/E (TTM)

Intraday

5D
Daily
Weekly
Monthly
1Q
1Y

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

Here's Why Jazz Pharmaceuticals (NASDAQ:JAZZ) Has Caught The Eye Of Investors
Simply Wall StFeb 17 13:09 ET
This AstraZeneca Analyst Turns Bullish; Here Are Top 5 Upgrades For Thursday
BenzingaFeb 13 07:35 ET
Wells Fargo Maintains Jazz Pharmaceuticals(JAZZ.US) With Buy Rating, Maintains Target Price $170
Moomoo NewsFeb 13 07:33 ET · Ratings
Jazz Pharmaceuticals Analyst Ratings
BenzingaFeb 13 06:18 ET · Ratings
Wells Fargo Upgrades Jazz Pharmaceuticals(JAZZ.US) to Buy Rating, Raises Target Price to $170
Moomoo NewsFeb 12 19:32 ET · Ratings
Jazz Pharmaceuticals Upgraded to Overweight From Equal Weight at Wells Fargo
TipRanksFeb 12 18:25 ET

Comments

Clintzilla

Feb 5 13:08

$Jazz Pharmaceuticals (JAZZ.US)$ just so you all know that this and $Sarepta Therapeutics (SRPT.US)$ are in the same area as $Cumberland Pharmaceuticals (CPIX.US)$ if you wanna know where CPIX price will be in the future

Meltyy

Nov 26, 2024 01:17

🚨 1 PDUFA this week!

See FDA PDUFA update 👇
$Applied Therapeutics (APLT.US)$ : 🤔
⇨ Govorestat
‣ Classic Galactosemia
‣ PDUFA: 11/28/24 (NDA)
🗓️ Last Week’s Adcom & PDUFA decisions:
$BridgeBio Pharma (BBIO.US)$ : Approved 11/22 ✅
⇨Attruby (Acoramidis)
‣ ATTR-CM (transthyretin amyloid cardiomyopathy)
‣ PDUFA: 11/29/24 (NDA)
$AstraZeneca (AZN.US)$ : Discussion, no vote
⇨ Andexxa (coagulation factor Xa)
‣ Life-threatening or uncontrolled bleeding
‣ Adcom: 11/21/24 (sBLA)
$Jazz Pharmaceuticals (JAZZ.US)$ & $Zymeworks (ZYME.US)$ : Approve...

Stock_Drift

Nov 20, 2024 18:32

$Jazz Pharmaceuticals (JAZZ.US)$

10xStockPicks

Oct 24, 2024 07:55

Hugely Undervalued $2 Biotech With 21% Held Short $16 Price Target, Takeover Candidate, Soon Profitable

Esperion $Esperion Therapeutics (ESPR.US)$ We reiterate Strong Buy rating. Esperion has the only FDA approved statin alternative drugs NEXLIZET & NEXLETOL for Primary Prevention, an estimated 21 Million Americans are Statin intolerant and or maxed out on Statin drugs and need additional lowering. Over 71 million Americans take statin drugs, we see continued prescription growth & expect over 5...

+20